Investor Presentaiton
Cardiovascular
milvexian
Camzyos
MYK-224
Opportunity for sustained leadership in Cardiovascular
1
Successful history of developing leading CV medicines (e.g., Plavix & Eliquis)
Extending our leadership in thrombotic diseases
•
Milvexian: Robust Phase 2 program supported differentiated clinical profile; Phase 3 studies in
SSP, ACS and AF underway
Potential opportunity for myosin inhibitors in cardiomyopathies and heart failure
Camzyos: Expansion into nHCM with Ph3 trial underway
MYK-224: Initiating PoC trial in HFPEF based on supportive data
Addressing cardiovascular diseases impacting 17M+1 patients
Ill Bristol Myers Squibb 1. Source: 2023 estimates from Decision Resource Group & BMS Internal Analysis across indications in the U.S. & EU5
Not for Product Promotional Use
125View entire presentation